Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent

Prostate

Volumn 68, Issue 2, 2008, Pages 183-189

  Makarov, Danil V ^a,b   Marlow, Cameron ^a   Epstein, Jonathan I ^a   Miller, M Craig ^c   Landis, Patricia ^a   Partin, Alan W ^a   Carter, H Ballentine ^a   Veltri, Robert W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Expectant management; Low grade and low stage cancer; Prostate biopsy; Prostate cancer; Quantitative nuclear grade

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; COHORT ANALYSIS; DEMOGRAPHY; DENSITY; DIGITAL IMAGING; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTIVARIATE ANALYSIS; NUCLEAR MORPHOMETRIC DESCRIPTOR; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; QUANTITATIVE NUCLEAR GRADE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR; VALIDATION PROCESS;

AGED; CELL NUCLEUS; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 38749108118     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20679     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-130.
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555-565.
3. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - What we have learned and where we are going. J Urol 1999;162(2):293-306.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
5. O'Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000;55(4):553-559.
6. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: Impact of changing disease demographics. Urology 2001;57(6):1105-1111.
7. Brawer MK, Benson MC, Bostwick DG, Djavan B, Lilja H, Semjonow A, Su S, Zhou Z. Prostate-specific antigen and other serum markers: Current concepts from the World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17(4):206-221.
8. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271(5):368-374.
9. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004;101(9):2001-2005.
10. Ghavamian R, Blute ML, Bergstralh EJ, Slezak J, Zincke H. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 1999; 54(1):105-110.
11. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: The new challenge. J Urol 2002;168(1):100-104.
12. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003; 170(3):723-726.
13. Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sozen S, Gill H. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 1998;160(6 Pt 2): 2412-2417.
14. Taylor SH, Merriman KW, Spiess PE, Pisters L. Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer. Cancer 2006;106(3):559-565.
15. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155(3):816-820.
16. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 1997;157(6):2206-2209.
17. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results. J Urol 2002;167(3):1231-1234.
18. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006;98(5):355-357.
19. Warlick CA, Allaf ME, Carter HB. Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy. Urol Oncol 2006;24(1):51-57.
20. Gill JE, Jotz MM. Further observations on the chemistry of pararosaniline-Feulgen staining. Histochemistry 1976;46:147-160.
21. Schulte E, Wittekind D. Standardization of the Feulgen-Schiff technique. Staining characteristics of pure fuchsin dyes; a cytophotometric investigation. Histochemistry 1989;91:321-331.
22. Veltri RW, Partin AW, Miller MC. Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations. J Cell Biochem Suppl 2000; (Suppl 35):151-157.
23. Sakr WA, Grignon DJ. Prostate cancer: Indicators of aggressiveness. Eur Urol 1997;32 (Suppl 3):15-23.
24. Allaf ME, Carter HB. Update on watchful waiting for prostate cancer. Curr Opin Urol 2004;14(3):171-175.
25. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95(9):634-635.
26. Katz EM, Kattan MW. How to judge a tumor marker. Nat Clin Pract Oncol 2005;2(10):482-483.
27. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003; 170(6 Pt 1):2274-2278.
28. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361): 955-964.
29. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
30. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(Spec No 1):R103-R121.
31. Getzenberg RH, Pienta KJ, Huang EY, Coffey DS. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 1991;51(24):6514-6520.
32. Stein GS, Berezney R, Getzenberg RH. Nuclear structure and cancer. J Cell Biochem 2000;79(S35):1-2.
33. Stein GS, Montecino M, van Wijnen AJ, Stein JL, Lian JB. Nuclear structure-gene expression interrelationships: Implications for aberrant gene expression in cancer. Cancer Res 2000;60(8):2067-2076.
34. Diamond DA, Berry SJ, Umbricht C, Jewett HJ, Coffey DS. Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 1982;3(4):321-332.
35. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: A critical analysis. J Urol 1989;142(5):1254-1258.
36. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI. Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992;70(1):161-168.
37. Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, Tindall DJ. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005;65(3):708-712.
38. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435(7046):1262-1266.
39. Bartels PH. Computer-generated diagnosis and image analysis. An overview. Cancer 1992;69 (6 Suppl):1636-1638.
40. Palcic B. Nuclear texture: Can it be used as a surrogate endpoint biomarker? J Cell Biochem Suppl 1994;19:40-46.
41. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, Coffey DS. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 1994;19:249-258.
42. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, Partin AW. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999;54(5):791-795.
43. Khan MA, Walsh PC, Miller MC, Bales WD, Epstein JI, Mangold LA, Partin AW, Veltri RW. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer 2003;98(12):2583-2591.
44. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10(10):3465-3473.
45. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O'Dowd GJ, Veltri RW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996;156(4):1375-1380.